FDAnews
www.fdanews.com/articles/178238-cardiocell-reports-positive-results-utilizing-iv-stem-cells-in-chronic-heart-failure

CardioCell Reports Positive Results Utilizing IV Stem Cells in Chronic Heart Failure

September 2, 2016

CardioCell released data from its Phase IIa trial studying the effects of intravenous administration of ischemia-tolerant mesenchymal stem cells in patients with chronic heart failure compared to placebo.

Results showed the injection was well-tolerated, with no major differences in safety endpoints.

The study also demonstrated improvements in the six-minute walk test, KCCQ Clinical Summary score, and trend to improvement in KCCQ Functional Status score. The injection also suppressed inflammation.

CardioCell said it plans to develop larger studies based on IV delivery in heart failure indications, both non-ischemic and ischemic cardiomyopathy.

View today's stories